Kyle Bass targets Alpex speckled tablet patent

25-11-2015

Kyle Bass targets Alpex speckled tablet patent

Roblan / Shutterstock.com

Hedge fund manager Kyle Bass has requested that the Patent and Trial and Appeal Board (PTAB) review the validity of a patent owned by Alpex Pharma.


Kyle Bass; USPTO; IPR; PTAB; Alpex Pharma; Suprenza; Erich Spangenberg

LSIPR